MYRIAD GENETICS INC (MYGN) — SEC Financial Statements & Analysis

MYRIAD GENETICS INC (MYGN) is a in vitro & in vivo diagnostic substances company, incorporated in DE. MYRIAD GENETICS INC trades on Nasdaq as: MYGN. MYRIAD GENETICS INC (MYGN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-31. Based on that filing, MYRIAD GENETICS INC carries a market cap of $541.31M, a P/E ratio of -4.59x, a P/B ratio of 1.78x, a P/S ratio of 0.68x, an enterprise value of $545.21M, and an EV/EBITDA multiple of -10.19x. On profitability, it posts a gross margin of 68.74%, an operating margin of -12.75%, a net margin of -14.76%, a Return on Equity (ROE) of -34.08%, a Return on Assets (ROA) of -17.92%, and a Return on Invested Capital (ROIC) of -14.68%. Per share, it reports EPS of $-1.24, diluted EPS of $-1.24, free cash flow per share of $-0.06, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -6.47% year-over-year, net income growth of -66.88% year-over-year, and EPS growth of -67.69% year-over-year. On the balance sheet, it maintains a current ratio of 2.21x, a quick ratio of 1.73x, working capital of $158.30M, a debt-to-equity ratio of 1.10x, a debt ratio of 0.52, an interest coverage ratio of -5.25x, free cash flow of $-5.60M (TTM), and net debt of $3.90M. Figures sourced from SEC EDGAR.

Market Cap

$541.31M

P/E TTM

-4.59x

EPS TTM

$-1.24

P/B TTM

1.78x

ROE TTM

-34.08%

ROA TTM

-17.92%

Debt To Equity

1.10x

Free Cash Flow TTM

$-5.60M

Net Revenue TTM Growth 1Y

-6.47%

Data as of 2026-06-30 · Source: SEC EDGAR